Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Conmed (CNMD) Research & Development (2016 - 2025)

Conmed's Research & Development history spans 16 years, with the latest figure at $14.9 million for Q4 2025.

  • For Q4 2025, Research & Development rose 13.08% year-over-year to $14.9 million; the TTM value through Dec 2025 reached $55.9 million, up 2.68%, while the annual FY2025 figure was $55.9 million, 2.68% up from the prior year.
  • Research & Development reached $14.9 million in Q4 2025 per CNMD's latest filing, up from $13.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $14.9 million in Q4 2025 to a low of $10.0 million in Q1 2021.
  • Average Research & Development over 5 years is $12.7 million, with a median of $12.9 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 30.09% in 2021, then fell 6.07% in 2024.
  • A 5-year view of Research & Development shows it stood at $11.4 million in 2021, then grew by 7.55% to $12.2 million in 2022, then rose by 14.8% to $14.0 million in 2023, then dropped by 6.07% to $13.2 million in 2024, then increased by 13.08% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Research & Development are $14.9 million (Q4 2025), $13.9 million (Q3 2025), and $14.1 million (Q2 2025).